Dyax - Advancing Novel Biotherapeutics

Dedicated to finding new solutions for patients in need.

Home>Investors>Investor Overview

Investor Overview

Webcast ImageWebcast
Dyax Corp. at Biotechnology Industry Organization CEO & Investor Conference (Replay)
Feb 8, 2010 at 10:30 a.m. ET
Profile

Dyax is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. We utilize our proprietary drug discovery technology, phage display, to identify antibody, small protein and peptide compounds for clinical development. Dyax also leverages this technology broadly with over 70 revenue generating licenses and collaborations for thera... 

More >>

Stock QuoteMore >>
DYAX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.22
Change (%) Stock is Down 0.16 (4.73%)
Volume228,428
Data as of Feb 8, 2010 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
Feb 2, 2010KALBITOR(R) (ecallantide) Now Commercially Available
KALBITOR Orders Being Coordinated Through KALBITOR AccessSM --Call 1-888-452-5248 or Visit www.KALBITOR.com for Information CAMBRIDGE, Mass., Feb 02, 2010 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ:DYAX) announced today that KALBITOR(R) (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older is now commercially available in the United States. HAE is a rare, genetic disorder characterized by severe, debilitating and often painful swelling... 
Printer Friendly Version
Feb 1, 2010Dyax Corp. to Present at the BIO CEO & Investor Conference
CAMBRIDGE, Mass., Feb 01, 2010 (BUSINESS WIRE) -- Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Gustav A Christensen, President and Chief Executive Officer of Dyax, will present at the 12th Annual BIO CEO & Investor Conference, being held February 8-9th at The Waldorf-Astoria Hotel in New York, NY. Mr. Christensen will present a corporate progress report, including an update on the Company's commercial activities for KALBITOR(R) ... 
Printer Friendly Version
Jan 14, 2010Dyax Launches HAE Hope, A New Online Resource for Patients with Hereditary Angioedema
Website Offers Tools for Recognizing Attack Triggers and Managing the DiseaseCAMBRIDGE, Mass., Jan 14, 2010 (BUSINESS WIRE) -- A new, online resource is now available for patients with hereditary angioedema (HAE), their caregivers and physicians. The website, www.HAEHope.com, launched today by Dyax Corp. (NASDAQ: DYAX), offers resources to help patients and their families better understand and manage HAE, a rare, genetic disease characterized by episodes of severe and painful swelling. A numbe... 
Printer Friendly Version
Dec 1, 2009Dyax Announces FDA Approval of KALBITOR(R) (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema in Patients 16 Years of Age and Older
First Subcutaneous Treatment Approved for HAE CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 1, 2009-- Dyax Corp. (NASDAQ:DYAX) announced today that the U.S. Food and Drug Administration (FDA) has granted approval for KALBITOR® (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. HAE is a rare, genetic disorder characterized by severe, debilitating and often painful s... 
Printer Friendly Version
Calendar of EventsMore >>
There are currently no events scheduled.
Event ArchivesMore >>
DateTitle
Oct 28, 2009
Download Documentation Q3 2009 Dyax Corp. Earnings Conference Call
Oct 5, 2009
Download Documentation Dyax Corp. at JMP Securities Healthcare Focus Conference
Sep 23, 2009
Download Documentation Dyax Corp. at UBS Global Life Sciences Conference
Get help downloading or viewing the above file types
Featured Financial ReportsMore >>
Filing DateForm
Nov 2, 200910-Q Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
Apr 15, 2009
2008 Annual Report

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Stock quote

ExchangeNASDAQ (US Dollar)
Price$3.22
Change (%) Stock is Down 0.16 (4.73%)
See more

IR Tool Kit

E-mail Alerts  E-mail Alerts
IR Contacts  IR Contacts
RSS Feeds  RSS Feeds
Investor Kit  Online Investor Kit

Investor Relations Contacts

Ivana Magovčević-Liebisch
Executive Vice President Corporate Development and General Counsel
Dyax Corp.
Phone: 617-225-2500


Nicole Jones
Director, Investor Relations and Corporate Communications
Dyax Corp.
Phone: 617-225-2500


Ellen Flipse Decareau
Senior Investor Relations and Corporate Communications Specialist
Dyax Corp.
Phone: 617-225-2500

See All